BRPI0506792A - derivados de furosemida como moduladores de hm74 e seu uso no tratamento de inflamação - Google Patents
derivados de furosemida como moduladores de hm74 e seu uso no tratamento de inflamaçãoInfo
- Publication number
- BRPI0506792A BRPI0506792A BRPI0506792-8A BRPI0506792A BRPI0506792A BR PI0506792 A BRPI0506792 A BR PI0506792A BR PI0506792 A BRPI0506792 A BR PI0506792A BR PI0506792 A BRPI0506792 A BR PI0506792A
- Authority
- BR
- Brazil
- Prior art keywords
- modulators
- furosemide
- treating inflammation
- derivatives
- furosemide derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54601104P | 2004-02-20 | 2004-02-20 | |
| PCT/US2005/004108 WO2005082350A1 (en) | 2004-02-20 | 2005-02-10 | Furosemide derivatives as modulators of hm74 and their use for the treatment of inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0506792A true BRPI0506792A (pt) | 2007-05-22 |
Family
ID=34910746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0506792-8A BRPI0506792A (pt) | 2004-02-20 | 2005-02-10 | derivados de furosemida como moduladores de hm74 e seu uso no tratamento de inflamação |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7232811B2 (https=) |
| EP (1) | EP1718292A1 (https=) |
| JP (1) | JP2007523166A (https=) |
| KR (1) | KR20060127141A (https=) |
| CN (1) | CN1921845A (https=) |
| AR (1) | AR047747A1 (https=) |
| AU (1) | AU2005216879B2 (https=) |
| BR (1) | BRPI0506792A (https=) |
| CA (1) | CA2557444A1 (https=) |
| CR (1) | CR8528A (https=) |
| EC (1) | ECSP066777A (https=) |
| IL (1) | IL177086A (https=) |
| MA (1) | MA28373A1 (https=) |
| ME (1) | MEP21108A (https=) |
| MX (1) | MXPA06008612A (https=) |
| NO (1) | NO20064237L (https=) |
| NZ (1) | NZ548830A (https=) |
| RS (1) | RS20060473A (https=) |
| RU (1) | RU2006133540A (https=) |
| SG (1) | SG164305A1 (https=) |
| TN (1) | TNSN06234A1 (https=) |
| TW (1) | TW200538109A (https=) |
| WO (1) | WO2005082350A1 (https=) |
| ZA (1) | ZA200606679B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8008283B2 (en) | 1998-12-23 | 2011-08-30 | Neurotherapeutics Pharma, Inc. | Methods and compositions for the treatment of neuropsychiatric disorders |
| WO2004083388A2 (en) | 2003-03-14 | 2004-09-30 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| CN101115726A (zh) | 2004-12-03 | 2008-01-30 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
| WO2007079470A2 (en) * | 2006-01-03 | 2007-07-12 | Algebra, Inc. | Therapeutic amine-arylsulfonamide conjugate compounds |
| AR059021A1 (es) * | 2006-01-18 | 2008-03-05 | Schering Corp | Moduladores de receptores cannabinoides |
| JP2010508300A (ja) * | 2006-10-26 | 2010-03-18 | フライン、ギャリー・エー． | アクアポリン修飾因子並びに浮腫および体液平衡異常の治療のためのそれらの使用方法 |
| US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
| US8623873B2 (en) * | 2007-06-28 | 2014-01-07 | Intervet Inc. | Substituted piperazines as CB1 antagonists |
| US20100286160A1 (en) * | 2007-06-28 | 2010-11-11 | Intervet Inc. | Substituted piperazines as cb1 antagonists |
| LT6401B (lt) | 2015-07-28 | 2017-06-12 | Vilniaus Universitetas | Karboanhidrazės selektyvūs inhibitoriai |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1260155A (en) * | 1969-04-29 | 1972-01-12 | Leo Pharm Prod Ltd | Sulphonamido anthranilic acid derivatives |
| US3875150A (en) | 1969-04-29 | 1975-04-01 | Leo Pharm Prod Ltd | New sulfamyl-anthranilic acids |
| DE2206424A1 (de) * | 1971-02-15 | 1972-08-24 | Dumex Ltd As | Verfahren zur Herstellung von N-substituierten Anthranilsäurederivaten |
| DE2247828A1 (de) * | 1972-09-29 | 1974-04-04 | Hoechst Ag | Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung |
| DE2406972C3 (de) * | 1974-02-14 | 1979-07-19 | Hoechst Ag, 6000 Frankfurt | Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren |
| DE2718871C3 (de) * | 1977-04-28 | 1980-07-17 | Hoechst Ag, 6000 Frankfurt | N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck |
| US4406896A (en) * | 1979-12-20 | 1983-09-27 | Merck & Co., Inc. | Adjuvants for rectal delivery of drug substances |
| DE3006686A1 (de) * | 1980-02-22 | 1981-08-27 | Hoechst Ag, 6000 Frankfurt | 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel |
| DE3041812A1 (de) * | 1980-11-06 | 1982-06-16 | Hoechst Ag, 6000 Frankfurt | Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel |
| DE3101960A1 (de) * | 1981-01-22 | 1982-09-02 | Hoechst Ag, 6000 Frankfurt | "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung" |
| US5256687A (en) * | 1985-09-09 | 1993-10-26 | Hoechst Aktiengesellschaft | Pharmaceutical composition for the treatment of high blood pressure |
| JPH0720862B2 (ja) * | 1989-01-27 | 1995-03-08 | ヘキスト・アクチエンゲゼルシヤフト | 吸入用喘息治療剤 |
| EP1007563A4 (en) * | 1997-06-12 | 2003-04-16 | Smithkline Beecham Corp | HM74A RECEPTOR |
| GB0021484D0 (en) * | 2000-09-01 | 2000-10-18 | Boehringer Ingelheim Pharma | Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases |
| DE10060809A1 (de) * | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker |
| US20030109673A1 (en) * | 2002-10-04 | 2003-06-12 | Xiao Yonghong | Regulation of human hm74-like g protein coupled receptor |
-
2005
- 2005-02-10 BR BRPI0506792-8A patent/BRPI0506792A/pt not_active IP Right Cessation
- 2005-02-10 JP JP2006554129A patent/JP2007523166A/ja active Pending
- 2005-02-10 CA CA002557444A patent/CA2557444A1/en not_active Abandoned
- 2005-02-10 WO PCT/US2005/004108 patent/WO2005082350A1/en not_active Ceased
- 2005-02-10 MX MXPA06008612A patent/MXPA06008612A/es active IP Right Grant
- 2005-02-10 EP EP05713210A patent/EP1718292A1/en not_active Withdrawn
- 2005-02-10 SG SG200901539-7A patent/SG164305A1/en unknown
- 2005-02-10 RS RSP-2006/0473A patent/RS20060473A/sr unknown
- 2005-02-10 AU AU2005216879A patent/AU2005216879B2/en not_active Ceased
- 2005-02-10 NZ NZ548830A patent/NZ548830A/en unknown
- 2005-02-10 RU RU2006133540/04A patent/RU2006133540A/ru not_active Application Discontinuation
- 2005-02-10 ME MEP-211/08A patent/MEP21108A/xx unknown
- 2005-02-10 CN CNA2005800054570A patent/CN1921845A/zh active Pending
- 2005-02-10 KR KR1020067016657A patent/KR20060127141A/ko not_active Withdrawn
- 2005-02-14 US US11/057,587 patent/US7232811B2/en not_active Expired - Fee Related
- 2005-02-18 TW TW094104731A patent/TW200538109A/zh unknown
- 2005-02-18 AR ARP050100596A patent/AR047747A1/es not_active Application Discontinuation
-
2006
- 2006-07-24 CR CR8528A patent/CR8528A/es not_active Application Discontinuation
- 2006-07-25 IL IL177086A patent/IL177086A/en not_active IP Right Cessation
- 2006-07-28 TN TNP2006000234A patent/TNSN06234A1/en unknown
- 2006-08-11 ZA ZA200606679A patent/ZA200606679B/xx unknown
- 2006-08-18 EC EC2006006777A patent/ECSP066777A/es unknown
- 2006-08-29 MA MA29295A patent/MA28373A1/fr unknown
- 2006-09-19 NO NO20064237A patent/NO20064237L/no not_active Application Discontinuation
-
2007
- 2007-05-07 US US11/745,131 patent/US7556931B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005216879A1 (en) | 2005-09-09 |
| CR8528A (es) | 2007-06-08 |
| AR047747A1 (es) | 2006-02-15 |
| RS20060473A (sr) | 2008-08-07 |
| TW200538109A (en) | 2005-12-01 |
| US7232811B2 (en) | 2007-06-19 |
| CN1921845A (zh) | 2007-02-28 |
| WO2005082350A8 (en) | 2005-12-08 |
| TNSN06234A1 (en) | 2007-12-03 |
| NZ548830A (en) | 2010-03-26 |
| AU2005216879B2 (en) | 2009-12-10 |
| SG164305A1 (en) | 2010-09-29 |
| US20070213391A1 (en) | 2007-09-13 |
| JP2007523166A (ja) | 2007-08-16 |
| IL177086A (en) | 2010-06-16 |
| RU2006133540A (ru) | 2008-03-27 |
| KR20060127141A (ko) | 2006-12-11 |
| US20050187280A1 (en) | 2005-08-25 |
| WO2005082350A1 (en) | 2005-09-09 |
| MEP21108A (en) | 2010-06-10 |
| EP1718292A1 (en) | 2006-11-08 |
| MA28373A1 (fr) | 2006-12-01 |
| IL177086A0 (en) | 2006-12-10 |
| NO20064237L (no) | 2006-09-19 |
| US7556931B2 (en) | 2009-07-07 |
| ZA200606679B (en) | 2008-01-30 |
| ECSP066777A (es) | 2006-11-16 |
| CA2557444A1 (en) | 2005-09-09 |
| MXPA06008612A (es) | 2007-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511477A (pt) | compostos e composições como moduladores de ppar | |
| CL2008002744A1 (es) | Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2. | |
| ECSP088283A (es) | Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
| CL2007003005A1 (es) | Compuestos derivados de [1,6]-naftiridinona, moduladores de la actividad cinasa; composicion farmaceutica que los comprende; y su uso para tratar trastornos proliferativos, inflamatorios, autoinmune, del sistema nervioso central, entre otros. | |
| MX382569B (es) | Compuesto de carboxamida, sulfonamida y amina para trastornos metabolicos. | |
| EA202091999A3 (ru) | Применение ингибиторов dpp iv | |
| ECSP088763A (es) | Nuevas combinaciones terapéuticas para el tratamiento de la depresión | |
| ECSP077275A (es) | Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos | |
| CL2008003393A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina, moduladores alostericos de los receptores de mglur2; composicion farmaceutica que comprende a dichos compuestos; y su uso en la preparacion de medicamentos para tratar trastornos del sistema nervioso central. | |
| SV2006002245A (es) | 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos ref. p-sv-78.797/msu | |
| CR8858A (es) | Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados | |
| ATE476418T1 (de) | Benzamidderivate und assoziierte verwendungen | |
| BRPI0814529A2 (pt) | Derivados de 2-3-dihidrobenzo[1,4]dioxin-2-ilmetil como antagonistas alfa2c para o uso no tratamento de doenças do sistema nervoso periférico e central. | |
| BRPI0510931A (pt) | derivados de sulfamato e sulfamida para o tratamento de epilepsia e distúrbios relacionados | |
| ECSP077277A (es) | Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas | |
| ECSP045473A (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 | |
| AR060536A1 (es) | Agonista del receptor de glucocorticoides y composiciones farmaceuticas | |
| UY31922A (es) | Compuestos | |
| MX2010005047A (es) | Inhibidores de aldh-2 en el tratamiento de enfermedades psiquiatricas. | |
| ECSP055964A (es) | Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
| BRPI0915439B8 (pt) | composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição | |
| BRPI0506792A (pt) | derivados de furosemida como moduladores de hm74 e seu uso no tratamento de inflamação | |
| BRPI0517438A (pt) | composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica | |
| ECSP088250A (es) | Derivados de pirazol como agentes terapéuticos | |
| BRPI0412809A (pt) | compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: AVENTIS PHARMACEUTICALS, INC. (US) , SANOFI-AVENTI Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007. |
|
| B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES. |
|
| B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |